Related Experiment Video
Updated: Mar 21, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1
Cheng-Cao Sun1, Shu-Jun Li1,2, De-Jia Li1
1Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, P. R. China.
Abstract:
Hsa-miRNA-134 (miR-134) has recently been discovered to have anticancer efficacy in different organs. However, the role of miR-134 on non-small cell lung cancer (NSCLC) is still ambiguous. In this study, we investigated the role of miR-134 on the development of NSCLC. The results indicated that miR-134 was significantly down-regulated in primary tumor tissues and very low levels were found in NSCLC cell lines. Ectopic expression of miR-134 in NSCLC cell lines significantly suppressed cell growth as evidenced by cell viability assay, colony formation assay and BrdU staining, through inhibition of cyclin D1, cyclin D2, CDK4 and up-regulation of p57(Kip2) and p21(Waf1/Cip1). In addition, miR-134 induced apoptosis, as indicated by concomitantly with up-regulation of key apoptosis protein cleaved caspase-3, and down-regulation of anti-apoptosis protein Bcl2. Moreover, miR-134 inhibited cellular migration and invasiveness through inhibition of matrix metalloproteinases (MMP)-7 and MMP-9. Further, oncogene CCND1 was revealed to be a putative target of miR-134, which was inversely correlated with miR-134 expression in NSCLC. Taken together, our results demonstrated that miR-134 played a pivotal role on NSCLC through inhibiting cell proliferation, migration, invasion, and promoting apoptosis by targeting oncogenic CCND1.
Insights
MicroRNA-134 (miR-134) shows promise as a tumor suppressor in non-small cell lung cancer (NSCLC). This study found miR-134 inhibits NSCLC cell growth, promotes apoptosis, and reduces migration by targeting CCND1.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- MicroRNA-134 (miR-134) exhibits anticancer properties in various cancers.
- The specific function of miR-134 in non-small cell lung cancer (NSCLC) remains unclear.
- Understanding miR-134's role is crucial for developing novel NSCLC therapies.
Purpose of the Study:
- To investigate the role and mechanism of miR-134 in the development of non-small cell lung cancer (NSCLC).
- To determine if miR-134 can suppress tumor progression in NSCLC.
Main Methods:
- Quantitative real-time PCR to measure miR-134 levels in NSCLC tissues and cell lines.
- Cell viability, colony formation, and BrdU assays to assess cell proliferation.
- Western blotting to analyze protein expression related to cell cycle, apoptosis, and invasion.
- Luciferase reporter assays to confirm CCND1 as a direct target of miR-134.
Main Results:
- miR-134 was significantly downregulated in NSCLC tissues and cell lines.
- Restoring miR-134 expression suppressed NSCLC cell proliferation by inhibiting cell cycle regulators (cyclin D1, cyclin D2, CDK4) and upregulating cell cycle inhibitors (p57Kip2, p21Waf1/Cip1).
- miR-134 induced apoptosis by upregulating cleaved caspase-3 and downregulating Bcl2.
- miR-134 inhibited cell migration and invasion by reducing MMP-7 and MMP-9 expression.
- CCND1 was identified as a direct target of miR-134, with inverse correlation observed in NSCLC.
Conclusions:
- miR-134 functions as a tumor suppressor in NSCLC.
- miR-134 inhibits proliferation, migration, and invasion while promoting apoptosis in NSCLC cells.
- Targeting CCND1 is a key mechanism through which miR-134 exerts its tumor-suppressive effects in NSCLC.
Related Concept Videos
MicroRNAs
MicroRNAs
lncRNA - Long Non-coding RNAs
Hedgehog Signaling Pathway
Abnormal Proliferation

